PMV Pharmaceuticals (PMV Pharmaceuticals) Market Cap : $104.95 Mil (As of May. 26, 2024)

View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PMV Pharmaceuticals's share price for the quarter that ended in Mar. 2024 was $1.7. PMV Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 51.45 Mil. Therefore, PMV Pharmaceuticals's market cap for the quarter that ended in Mar. 2024 was $87.46 Mil.

PMV Pharmaceuticals's quarterly market cap declined from Sep. 2023 ($314.11 Mil) to Dec. 2023 ($159.48 Mil) and declined from Dec. 2023 ($159.48 Mil) to Mar. 2024 ($87.46 Mil).

PMV Pharmaceuticals's annual market cap declined from Dec. 2021 ($1,049.52 Mil) to Dec. 2022 ($398.21 Mil) and declined from Dec. 2022 ($398.21 Mil) to Dec. 2023 ($159.48 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PMV Pharmaceuticals's Enterprise Value for Today is $-79.97 Mil.

PMV Pharmaceuticals Market Cap Historical Data

The historical data trend for PMV Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals Market Cap Chart

PMV Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

2,754.28

1,049.52

398.21

159.48

PMV Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Market Cap	Get a 7-Day Free Trial															218.35	288.86	314.11	159.48	87.46

Competitive Comparison of PMV Pharmaceuticals's Market Cap

For the Biotechnology subindustry, PMV Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PMV Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's Market Cap falls into.

PMV Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

PMV Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$3.1	*	51.4459
	=	$159.48

PMV Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )	=	Share Price (Q: Mar. 2024 )	*	Shares Outstanding (EOP) (Q: Mar. 2024 )
	=	$1.7	*	51.4459
	=	$87.46

PMV Pharmaceuticals (NAS:PMVP) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

PMV Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Research Way, Princeton, NJ, USA, 08536

Website

https://www.pmvpharma.com

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

Executives

Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland	officer: Chief Medical Officer	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota	officer: SVP, Regulatory Affairs and QA	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder	director, 10 percent owner	C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung	officer: COO, CFO	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack	director, officer: President and CEO	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc	10 percent owner	160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons	10 percent owner	RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc	10 percent owner	C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010